Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E18.70 EPS (ttm)3.88 Insider Own0.10% Shs Outstand1.60B Perf Week2.24%
Market Cap116.01B Forward P/E11.13 EPS next Y6.53 Insider Trans-20.82% Shs Float1.59B Perf Month10.18%
Income6.31B PEG1.29 EPS next Q1.40 Inst Own70.30% Short Float1.91% Perf Quarter10.70%
Sales26.22B P/S4.42 EPS this Y16.20% Inst Trans1.29% Short Ratio5.40 Perf Half Y18.21%
Book/sh3.13 P/B23.21 EPS next Y18.18% ROA9.50% Target Price74.22 Perf Year18.48%
Cash/sh3.91 P/C18.57 EPS next 5Y14.45% ROE116.10% 52W Range55.06 - 73.67 Perf YTD16.00%
Dividend2.56 P/FCF42.31 EPS past 5Y10.90% ROI18.00% 52W High-1.40% Beta1.54
Dividend %3.52% Quick Ratio1.60 Sales past 5Y8.00% Gross Margin76.70% 52W Low31.92% ATR0.96
Employees30000 Current Ratio1.80 Sales Q/Q9.70% Oper. Margin36.30% RSI (14)79.69 Volatility1.52% 1.28%
OptionableYes Debt/Eq7.39 EPS Q/Q28.10% Profit Margin24.10% Rel Volume1.25 Prev Close73.18
ShortableYes LT Debt/Eq7.31 EarningsJul 27 BMO Payout60.20% Avg Volume5.63M Price72.64
Recom2.40 SMA205.32% SMA508.59% SMA20014.47% Volume7,027,733 Change-0.74%
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Jun-24-17 08:16AM  3 Dividend Stocks Perfect for Retirement Motley Fool
Jun-23-17 11:05AM  [$$] Samsung Makes Play for Drug Market With Version of Blockbuster Humira The Wall Street Journal
08:47AM  AbbVie Receives CHMP Positive Opinion for MAVIRET (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) PR Newswire
08:06AM  AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know Motley Fool
Jun-22-17 11:27PM  Time To Buy Lagging Healthcare Stocks Forbes
06:50PM  Cramer's lightning round: Don't go down the food chain in this space CNBC
03:52PM  AbbVie Declares Quarterly Dividend PR Newswire
07:38AM  Inside Vertex Pharmaceuticals Revenue Trend Market Realist
Jun-20-17 04:27PM  Which Stocks Are Showing Rising Relative Strength? Investor's Business Daily
02:39PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
11:28AM  J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study Zacks
07:11AM  Better Buy: Pfizer Inc. vs. AbbVie Inc. Motley Fool
Jun-19-17 04:15PM  As Clovis Oncology Soars, This Big Pharma Stock Clears New Buy Zone Investor's Business Daily
02:49PM  ETFs with exposure to AbbVie, Inc. : June 19, 2017 Capital Cube
10:28AM  AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run? Zacks
Jun-18-17 11:01AM  AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher Motley Fool
Jun-16-17 04:41PM  Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs? Investor's Business Daily
09:34AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
08:07AM  3 Dividend Stocks in Healthcare Motley Fool
Jun-15-17 04:10PM  Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J TheStreet.com
10:43AM  3 Stocks With Better Dividends Than CVS Health Corporation Motley Fool
10:36AM  Analysts Recommendations for AbbVie in June 2017 Market Realist
09:06AM  This Product Pipeline Brings Hope for AbbVies Future Growth Market Realist
07:36AM  How Is AbbVie Expected to Perform in 2017? Market Realist
07:36AM  3 Dividend Stocks for Astute Investors Motley Fool
Jun-14-17 10:36AM  A Look at AbbVies Neuroscience Portfolio Market Realist
09:06AM  Why Lupron Could Continue to Generate Steady Revenue Market Realist
07:37AM  Why Viekira Could Witness a Modest Revenue Fall in 2017 Market Realist
Jun-13-17 03:03PM  How AbbVie Inc. Makes Most of Its Money Motley Fool
02:05PM  An Overview of Imbruvicas and Venclextas Clinical Pipelines Market Realist
12:35PM  Imbruvica May Witness Significant Revenue Growth in 2017 Market Realist
12:03PM  Top 4 Marijuana Stocks to Watch for 2017 Investopedia
10:45AM  Humira May Continue to Drive AbbVies Revenue Growth Market Realist
08:30AM  AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors PR Newswire
Jun-12-17 10:59AM  FDA rejects Coherus's biosimilar for Neulasta, shares plunge Reuters
10:47AM  Moody's: Patent invalidation creates risk for US branded drug makers Moody's
12:00AM  [$$] Big US pharma dealmaking plunges to five-year low Financial Times
Jun-09-17 04:15PM  AbbVie must pay $15 mln in Depakote birth-defect trial: jury Reuters
01:22PM  AbbVie suffers $15 million loss in Depakote birth-defect trial Reuters
12:41PM  AbbVie Ordered by Jury to Pay $15 Million to Depakote Victim Bloomberg
10:23AM  3 Dividend Stock Winners Motley Fool
Jun-08-17 02:41PM  The Best Hep C Drug Stock to Buy in 2017 Motley Fool
10:10AM  AbbVie (ABBV) Announced Positive Phase III RA Candidate Data Zacks
Jun-07-17 07:05PM  AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher TheStreet.com
02:23PM  UPDATE 3-AbbVie's rheumatoid arthritis drug succeeds in trial Reuters
08:11AM  AbbVie's rheumatoid arthritis drug succeeds in late-stage trial Reuters
08:08AM  AbbVie says late-stage rheumatoid arthritis trial had positive results MarketWatch
08:04AM  3 Cheap Stocks You Can Buy Today Motley Fool
07:56AM  AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis PR Newswire
Jun-05-17 07:00AM  New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients PR Newswire
07:00AM  Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease PR Newswire
05:00AM  AbbVie Testosterone Gel Faces Scrutiny as First Trial Begins Bloomberg
Jun-04-17 08:21AM  3 Dividend Aristocrats To Buy -- And 2 To Sell Forbes
Jun-03-17 07:33AM  3 Stocks With Something for Everyone Motley Fool
Jun-02-17 11:03AM  Is This Dividend Aristocrat Ridiculously Undervalued? Motley Fool
May-30-17 07:37AM  What Analysts Recommend for Gilead Sciences in May 2017 Market Realist
May-28-17 11:03AM  3 Top Dividend Stocks in Cancer Drugs Motley Fool
May-27-17 12:03PM  The 2 Best Dividend Stocks in Marijuana Motley Fool
08:40AM  Top Presentations to Look for at ASCO 24/7 Wall St.
May-26-17 08:15AM  Blog Coverage: Pfizer Cautions Shareholders Against Accepting TRC Capital Corporation's Mini-Tender Offer Accesswire
May-25-17 09:45AM  Major Pharma Short Interest Surges 24/7 Wall St.
09:16AM  Biogen's Fampyra Conditional Approval Converted to Standard Zacks
May-24-17 10:37AM  Neupogen and Enbrel Could See Falling Revenues in 2017 Market Realist
08:00AM  AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference PR Newswire
May-23-17 04:49PM  AbbVie Expects Rivals To Chip Away At Its Biggest Drug Franchise Investor's Business Daily
04:25PM  Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis Investor's Business Daily
May-22-17 08:42AM  The 3 Best Dividend Stocks in Arthritis Medication Motley Fool
May-20-17 01:23AM  [$$] AmerisourceBergen and AbbVie Top Barron's 500 Barrons.com
May-19-17 09:30AM  The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco Zacks
08:00AM  AbbVie to Present at the Jefferies 2017 Global Healthcare Conference PR Newswire
May-18-17 07:00PM  For millions of Chinese with rare diseases, some relief in sight Reuters
04:37PM  AbbVie's Humira Loses Patent in Coherus' Petitions GuruFocus.com
12:48PM  New Stock Research Reports for Boeing, AbbVie and UnitedHealth Zacks
11:17AM  [$$] AbbVie: It's the Pipeline, Not the Coherus Ruling Barrons.com
09:23AM  AbbVie Down on Humira Patent Loss: Is More Damage in Store? Zacks
08:40AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : May 18, 2017 Capital Cube
May-17-17 05:02PM  AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech Investor's Business Daily
05:00PM  AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
02:55PM  Humira Ruling Is A 'Big Victory' For Coherus Barrons.com
12:10PM  Why This Humira Patent Loss Might Not Be What You Think 24/7 Wall St.
12:00PM  AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis PR Newswire
10:53AM  AbbVie Stock Lower on Humira Patent Ruling TheStreet.com
10:14AM  AbbVie: Losing Humira Patent Isn't The End Barrons.com
09:20AM  Morning Moves: Colgate, Target Climb; AbbVie Sinks; Disney Dips Barrons.com
07:35AM  US STOCKS-Futures slide as concerns over Trump spook investors Reuters
May-16-17 04:51PM  This Funds Picks Gained 200% In A Year And Why No One Knows About It Insider Monkey
03:42PM  3 Best Dividend Stocks in Biotech Motley Fool
May-15-17 06:47PM  Cramer's lightning round: This car company's not encouraging you to buy stock CNBC
10:30AM  AbbVie and J&J Present Positive Imbruvica Leukemia Data Zacks
May-14-17 05:00PM  IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) PR Newswire
May-10-17 04:21PM  Investors Are Betting Big Against Marijuana Stock Insys Therapeutics -- Why They're Wrong Motley Fool
08:05AM  Why Gilead Sciences Stock Lagged Behind Other Biotechs in April Motley Fool
May-09-17 11:00AM  AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease PR Newswire
May-06-17 07:25AM  Which Big Pharma Is the Best Dividend Stock? Motley Fool
May-05-17 12:43PM  AbbVie to Present at the UBS Global Healthcare Conference PR Newswire
07:20AM  S&P Dividend Aristocrats: Which Stocks Make the List? Motley Fool
May-04-17 04:21PM  A Big, New Threat to Gilead Sciences Is Coming Motley Fool
09:00AM  AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week® PR Newswire
May-03-17 03:43PM  5 Things AbbVie Management Just Said That You'll Want to Know Motley Fool
May-02-17 06:24PM  Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales Motley Fool
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM